Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

I like this structure because, if one area faces headwinds ... The company is developing VK2735 in injectable and oral formulations. The injectable is set to start a phase 3 trial in Q2, and ...

Although there is little to no current profitability, these stocks have significant upside potential and pose an “option-like structure ... s lead program, VK2735, is a source of optimism ...

Although there is little to no current profitability, these stocks have significant upside potential and pose an “option-like structure ... s lead program, VK2735, is a source of optimism ...

When you first enter a new world, you can either spawn near a structure or find one while exploring any of the three dimensions. While finding some can be quite easy, others are extremely hard to ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7 ...

In the second quarter of 2025, the business intends to start Phase 3 studies for their subcutaneous obesity therapy, VK2735. Targeting metabolic and endocrine diseases, the San Diego-based ...

While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure ...